Alzheimer’s Research Part 1
Although there is still no conclusive test for the determination of Alzheimer’s disease (AD), there is hope and occasionally, new information. Last month, Science Daily reported that:
Elderly people exhibiting memory disturbances that do not affect their normal, daily life suffer from a condition called “mild cognitive impairment” (MCI). Some MCI patients go on to develop Alzheimer’s disease within a few years, whereas other cases remain stable, exhibiting only benign senile forgetfulness. It is crucial to develop simple, blood-based tests enabling early identification of these patients that will progress in order to begin therapy as soon as possible, potentially delaying the onset of dementia.
A group of investigators, led by Professor Massimo Tabaton of the University of Genoa, Italy, have data that sheds light on this issue. The results of their research are published in the October issue of the Journal of Alzheimer’s Disease.
The investigators report that the concentration in blood of amyloid beta “42,” the toxic molecule that is believed to be the main cause of Alzheimer’s disease, is, on average, higher in MCI cases that went on to develop Alzheimer’s disease approximately three years later. The values of amyloid beta in blood vary considerably among the patient groups examined (MCI that develop Alzheimer’s disease; MCI stable; normal subjects). “This variability is likely very important,” Dr. Tabaton noted and went on to add, “but means that this needs further work before we can use this test for a definitive diagnosis.” For example, the scientists are going to set up a test that picks up a variant of amyloid beta potentially more specific of the disease.
There’s progress, but we still have a long ways to go to find an effective test. A conclusive blood test would certainly be ideal. But even if we were to have a conclusive test, doctors still have very few effective treatments for Alzheimer’s disease. And still, as it has been for a long time, only an autopsy will reveal definitively whether or not a person truly had Alzheimer’s.
Tagged with: Alzheimer • Alzheimer Disease • Alzheimer Research • Alzheimer S Disease • Alzheimer S Research • Alzheimer's Disease • Alzheimer's Research • amyloid beta • Amyloid beta 42 • Blood Test • Body Chemistry • Brain Changes • Brain Volume • Concentration • Conclusive Test • Definitive Diagnosis • Dementia • Doctors • Followers • Forgetfulness • Genoa Italy • Investigators • Irish Researchers • Journal of Alzheimer's Disease • Long Tim • Massimo • Massimo Tabaton • Memory • Memory Tests • Mild Cognitive Impairment • Mild Cognitive Impairment Mci • Molecule • Nature Talk • New Drugs • Patient Groups • Reuters • Science Daily • Scientists • University of Genoa Italy • Variability • Vienna Austria • Website Visitors • Word Of Mouth • Word Of Mouth Advertising
Filed under: Alzheimer's Disease • Alzheimer's Disease Research
Like this post? Subscribe to my RSS feed and get loads more!

Leave a Reply